

Other version: http://www.springerlink.com/content/f163738p71125530/fulltext.html
![]() |
Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment |
|
Authors | ![]() | |
Published in | Psychopharmacology. 2009, vol. 206, no. 2, p. 313-24 | |
Abstract | RATIONALE: Dopamine D2 receptors are the main target of antipsychotic drugs. In the brain, D2 receptors coexpress with adenosine A2A and CB1 cannabinoid receptors, leading to functional interactions. OBJECTIVES: The protein and messenger RNA (mRNA) contents of A2A, D2, and CB1 receptors were quantified in postmortem prefrontal cortex of subjects with schizophrenia. MATERIALS AND METHODS: The study was performed in subjects suffering schizophrenia (n=31) who mainly died by suicide, matched with non-schizophrenia suicide victims (n=13) and non-suicide controls (n=33). The density of receptor proteins was evaluated by immunodetection techniques, and their relative mRNA expression was quantified by quantitative real-time polymerase chain reaction. RESULTS: In schizophrenia, the densities of A2A (90+/-6%, n=24) and D2-like receptors (95+/-5%, n=22) did not differ from those in controls (100%). Antipsychotic treatment did not induce changes in the protein expression. In contrast, the immunodensity of CB1 receptors was significantly decreased (71+/-7%, n=11; p<0.05) in antipsychotic-treated subjects with schizophrenia but not in drug-free subjects (104+/-13%, n=11). The relative mRNA amounts encoding for A2A, D2, and CB1 receptors were similar in brains of drug-free, antipsychotic-treated subjects with schizophrenia and controls. CONCLUSIONS: The findings suggest that antipsychotics induce down-regulation of CB1 receptors in brain. Since A2A, D2, and CB1 receptors coexpress on brain GABAergic neurons and reductions in markers of GABA neurotransmission have been identified in schizophrenia, a lower density of CB1 receptor induced by antipsychotics could represent an adaptative mechanism that reduces the endocannabinoid-mediated suppression of GABA release, contributing to the normalization of cognitive functions in the disorder. | |
Keywords | Adult — Aged — Analysis of Variance — Antipsychotic Agents/pharmacology/therapeutic use — Female — Frontal Lobe/drug effects — Gene Expression Regulation/drug effects/genetics — Humans — Male — Middle Aged — Postmortem Changes — RNA, Messenger/metabolism — Receptor, Adenosine A2A/genetics/metabolism — Receptor, Cannabinoid, CB1/genetics/metabolism — Receptors, Dopamine D2/genetics/metabolism — Schizophrenia/drug therapy/metabolism/pathology — Suicide/psychology — Young Adult | |
Identifiers | PMID: 19652957 | |
Full text |
![]() ![]() Other version: http://www.springerlink.com/content/f163738p71125530/fulltext.html |
|
Structures | ||
Research group | Neurorécepteurs et ARN (672) | |
Citation (ISO format) | URIGÜEN, Leyre et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. In: Psychopharmacology, 2009, vol. 206, n° 2, p. 313-24. doi: 10.1007/s00213-009-1608-2 https://archive-ouverte.unige.ch/unige:5538 |